3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines inhibit tubulin polymerisation and act as anticancer agents

References

• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010;9:790–803.
   PubMed Web of Science ®Google Scholar
• Steinmetz MO, Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol. 2018;28:776–792.
   PubMed Web of Science ®Google Scholar
• Kaul R, Risinger AL, Mooberry SL. Microtubule-targeting drugs: more than antimitotics. J. Nat. Prod. 2019;82:680–685.
   PubMed Web of Science ®Google Scholar
• Lawrence EJ, Zanic M. Rescuing microtubules from the brink of catastrophe: CLASPs lead the way. Curr Opin Cell Biol. 2019;56:94–101.
   PubMed Web of Science ®Google Scholar
• Cermak V, Dostal V, Jelínek M, Libusova L, Kovar J, Rosel D, Brabek J. Microtubule-targeting agents and their impact on cancer treatment. Eur. J. Cell Biol. 2020;99:151075.
   PubMed Web of Science ®Google Scholar
• Pettit G, Singh S, Hamel E, Lin CM, Alberts D, Garcia-Kendal D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45:209–211.
   PubMedGoogle Scholar
• Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J. Med. Chem. 1995;38:1666–1672.
   PubMed Web of Science ®Google Scholar
• Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A 4: present and future directions. J. Med. Chem. 2006;49:3033–3044.
   PubMed Web of Science ®Google Scholar
• Li Q, Sham HL. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer, Expert. Opin. Ther. Pat. 2002;12(11):1663–1702.
   Web of Science ®Google Scholar
• Mustafa M, Anwar S, Elgamal F, Ahmed ER, Aly OM. Potent combretastatin A-4 analogs containing 1,2,4-triazole: synthesis, antiproliferative, anti-tubulin activity, and docking study. Eur J Med Chem. 2019;183:111697.
   PubMed Web of Science ®Google Scholar
• Perez-Perez MJ, Priego EM, Bueno O, Martins MS, Canela MD, Liekens S. Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth. J Med Chem. 2016;59:8685–8711.
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Gorbounova V, Reck M, Kowalski DM, Allard A, Chadjaa M, Rey A, Bennouna J, Grossi F. DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. Lung Cancer. 2014;85:224–229.
   PubMed Web of Science ®Google Scholar
• Metzler M, Neumann H. Epoxidation of the stilbene double bond, a major pathway in aminostilbene metabolism. Xenobiotica. 1977;7:117–132.
   PubMed Web of Science ®Google Scholar
• Wang C, Yang S, Du J, Ni J, Wu Y, Wang J, Guan Q, Zuo D, Bao K, Wu Y, et al. Synthesis and bioevaluation of diarylpyrazoles as antiproliferative agents. Eur. J. Med. Chem. 2019;171:1–10.
   PubMed Web of Science ®Google Scholar
• Odlo K, Fournier-Dit-Chabert J, Ducki S, Gani OA, Sylte I, Hansen TV. 1, 2, 3-Triazole analogs of combretastatin A-4 as potential microtubule-binding agents. Bioorg. Med. Chem. 2010;18:6874–6885.
   PubMed Web of Science ®Google Scholar
• Theeramunkong S, Caldarelli A, Massarotti A, Aprile S, Caprioglio D, Zaninetti R, Teruggi A, Pirali T, Grosa G, Tron GC, et al. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues. J Med Chem. 2011;54(14):4977–4986.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liang YR, Li H, Liu MM, Wang Y. Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents. Bioorg. Med. Chem. 2017;25:6623–6634.
   PubMedGoogle Scholar
• Kumar D, Patel G, Chavers AK, Chang KH, Shah K. Synthesis of novel 1, 2, 4-oxadiazoles and analogues as potential anticancer agents. Eur. J. Med. Chem. 2011;46:3085–3092.
   PubMed Web of Science ®Google Scholar
• Kamal A, Dastagiri D, Ramaiah MJ, Bharathi EV, Reddy JS, Balakishan G, Sarma P, Pushpavalli SNCVL, Pal-Bhadra M, Juvekar A, et al. Synthesis, anticancer activity and mitochondrial mediated apoptosis inducing ability of 2, 5-diaryloxadiazoleepyrrolobenzodiazepine conjugates. Bioorg Med Chem. 2010;18(18):6666–6677.,
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Leeson PA, Castaner J. AMP-579: treatment of acute myocardial infarction adenosine A1/A(2A) agonist, Drug. Future. 1998;23:847–859.
   Google Scholar
• Shi A, Zhang L, Wan H, Wang S, Yang M, Guan Q, Bao K, Zhang W. Design, synthesis and bioevaluation of 2-mercapto-6-phenylpyrimidine-4-carboxylic acid derivatives as potent xanthine oxidase inhibitors. Eur. J. Med. Chem. 2018;155:590–595.
   PubMed Web of Science ®Google Scholar
• Baxter PN. Synthesis and fluorescence ion-sensory properties of the first dehydropyridoannulene-type cyclophane with enforced exotopic metal ion binding sites. Chemistry. 2003;9(11):2531–2541.
   PubMed Web of Science ®Google Scholar
• Imahori T, Uchiyama M, Sakamoto T, Kondo Y. Regiocontrolled deprotonative-zincation of bromopyridines using aminozincates. Chem. Commun (Camb). 2001;23:2450–2451.
   Google Scholar
• Liu R, Huang M, Zhang S, Li L, Li M, Sun J, Wu L, Guan Q, Zhang W. Design, synthesis and bioevaluation of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazoles as tubulin polymerization inhibitors. Eur. J. Med. Chem. 2021;226:113826.
   PubMed Web of Science ®Google Scholar
• Shi L, Yang S, Chang J, Zhang Y, Liu W, Zeng J, Meng J, Zhang R, Wang C, Xing D. Design, synthesis and biological evaluation of 9-aryl-5H-pyrido[4,3-b]indole derivatives as potential tubulin polymerization inhibitors. Front. Chem. 2022;10:1004835.
   PubMed Web of Science ®Google Scholar
• Yang S, Wang C, Shi L, Chang J, Zhang Y, Meng J, Liu W, Zeng J, Zhang R, Shao Y, et al. Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors. J. Enzyme. Inhib. Med. Chem. 2022;37(1):2755–2764.
   PubMed Web of Science ®Google Scholar
• Wang C, Li Y, Liu Z, Wang Z, Liu Z, Man S, Zhang Y, Bao K, Wu Y, Guan Q, et al. Design, synthesis and biological evaluation of 1-Aryl-5-(4-arylpiperazine-1-carbonyl)-1H-tetrazols as novel microtubule destabilizers. J. Enzyme. Inhib. Med. Chem. 2021;36(1):549–560.
   PubMed Web of Science ®Google Scholar
• Yang XC, Cheng BB, Xiao Y, Xue MM, Liu T, Cao H, Chen JJ. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. Eur. J. Med. Chem. 2021;213:113058.
   PubMed Web of Science ®Google Scholar
• Deng B, Sun Z, Wang Y, Mai R, Yang Z, Ren Y, Liu J, Huang Ma Z, Chen T, Zeng, C, et al. Design, synthesis, and bioevaluation of imidazo [1,2-a] pyrazine derivatives as tubulin polymerization inhibitors with potent anticancer activities. Bioorg Med Chem. 2022;76:117098.
   PubMed Web of Science ®Google Scholar
• Sana S, Reddy VG, Srinivasa Reddy T, Tokala R, Kumar R, Bhargava SK, Shankaraiah N. Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell growth inhibition studies. Bioorg Chem. 2021;110:104765.
   PubMed Web of Science ®Google Scholar
• Parupalli R, Akunuri R, Spandana A, Phanindranath R, Pyreddy S, Bazaz MR, Vadakattu M, Joshi SV, Bujji S, Gorre B, et al. Synthesis and biological evaluation of 1-phenyl-4,6-dihydrobenzo[b]pyrazolo[3,4-d]azepin-5(1H)-one/thiones as anticancer agents. Bioorg Chem. 2023;135:106478.
   PubMed Web of Science ®Google Scholar